巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    虛擬市場

    VYNE Therapeutics

    VYNE
    0.330
    ▼0.010
    ▼3.20%
    概況消息
    最少15分鐘延遲，股票資訊由第三方資訊供應商提供
    ・VYNE Therapeutics - 延遲價格・最後更新於 18/08 7:30
    最高位
    0.347
    最低位
    0.321
    開市價
    --
    前收市價
    0.341
    成交量(千)
    4.40
    成交額(百萬)
    0.01
    買入
    0.331
    賣出
    0.336
    每手股數
    --
    市值(百萬)
    19.15
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    1.750 - 0.256
    所有資料不保證絕對正確、完整、或實時，僅作為參考使用。投資涉及風險，過往業績並不代表將來表現，作任何投資決定或交易前，閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    VYNE Therapeutics
    證券代碼
    VYNE.US
    所屬板塊
    Biotechnology
    公司業務
    VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its most advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ and ZILXI.
    發行量
    57833192
    公司總部
    520 U.S. Highway 22, Suite 204
    公司網址
    https://www.vynetherapeutics.com
    公司電郵
    ir@menlotx.com
    公司電話
    +1 800 775-7936

    最新發佈

    暫無內容

    關於

    VYNE Therapeutics(VYNE.US)所屬的行業板塊為Biotechnology。
    VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its most advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ and ZILXI.
    詳細公司背景可參考: https://www.vynetherapeutics.com。